Compare stocks

Straumann Holding AG is a global company specializing in the manufacture and supply of dental implants, orthodontic products, and digital dentistry tools. Headquartered in Basel, Switzerland, the company's products include dental implants, prosthetics, digital equipment, and biomaterials, serving both dental professionals and patients worldwide. Straumann has grown through strategic acquisitions, expanding its footprint in digital and orthodontic technologies. The company operates in various international markets, leveraging a strong focus on innovation and partnerships to maintain its competitive advantage in the dental industry. Its strategic positioning is supported by a commitment to research and development, ensuring continuous advancements in dental solutions.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.